At the time of writing, Sagimet Biosciences Inc [SGMT] stock is trading at $7.68, down -10.96%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SGMT shares have gain 5.28% over the last week, with a monthly amount glided 9.02%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sagimet Biosciences Inc [NASDAQ: SGMT] stock has seen the most recent analyst activity on August 11, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $28. On July 24, 2025, Canaccord Genuity initiated with a Buy rating and assigned a price target of $28 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $30 on December 06, 2024. UBS initiated its recommendation with a Buy and recommended $12 as its price target on November 12, 2024. Goldman downgraded its rating to Neutral for this stock on June 28, 2024, and downed its price target to $6. In a note dated May 02, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $32 on this stock.
For the past year, the stock price of Sagimet Biosciences Inc fluctuated between $1.73 and $11.41. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Sagimet Biosciences Inc [NASDAQ: SGMT] shares were valued at $7.68 at the most recent close of the market. An investor can expect a potential drop of -21.87% based on the average SGMT price forecast.
Analyzing the SGMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.4 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Sagimet Biosciences Inc [NASDAQ:SGMT] has a current ratio of 17.47. Further, the Quick Ratio stands at 17.47, while the Cash Ratio is 5.84.
Transactions by insiders
Recent insider trading involved Happel David, President & CEO, that happened on Jul 21 ’25 when 65478.0 shares were sold. Chief Medical Officer, Martins Eduardo Bruno completed a deal on Jul 21 ’25 to sell 8277.0 shares. Meanwhile, General Counsel and CCO Rozek Elizabeth sold 10780.0 shares on Jul 21 ’25.
